Daniel S. Lorrain
Chief Scientific Officer · 11 filings · Latest: Jul 8, 2026
Contineum Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
CTNM | Daniel S. Lorrain | Chief Scientific Officer | Feb 24, 2026 | Option Exercise | $1.01 | 4,300 | $4.3K | 160,352 | |
CTNM | Daniel S. Lorrain | Chief Scientific Officer | Feb 19, 2026 | Sale | $16.00 | 100 | $1.6K | 156,052 | |
CTNM | Daniel S. Lorrain | Chief Scientific Officer | Feb 19, 2026 | Option Exercise | $1.01 | 100 | $101 | 156,152 | |
CTNM | Daniel S. Lorrain | Chief Scientific Officer | Feb 11, 2026 | Sale | $16.00 | 400 | $6.4K | 156,052 | |
CTNM | Daniel S. Lorrain | Chief Scientific Officer | Feb 11, 2026 | Option Exercise | $1.01 | 400 | $404 | 156,452 | |
CTNM | DANIEL LORRAIN | — | Feb 11, 2026 | Proposed Sale | $15.75 | 16,050 | $252.8K | — | |
CTNM | Daniel S. Lorrain | Chief Scientific Officer | Feb 3, 2026 | Sale | $14.94 | 4,170 | $62.3K | 156,052 | |
CTNM | DANIEL LORRAIN | — | Feb 3, 2026 | Proposed Sale | $14.38 | 4,170 | $60.0K | — | |
CTNM | DANIEL LORRAIN | — | Jan 5, 2026 | Proposed Sale | $11.39 | 4,170 | $47.5K | — | |
CTNM | DANIEL LORRAIN | — | Dec 23, 2025 | Proposed Sale | $12.26 | 4,170 | $51.1K | — | |
CTNM | DANIEL LORRAIN | — | Nov 18, 2024 | Proposed Sale | $17.21 | 26,370 | $453.8K | — |
← Previous
Page 2 of 2